Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing GLSI-100, an immunotherapy vaccine that combines a HER2-derived peptide with GM-CSF to prevent breast cancer recurrences in HER2-positive patients. The company is advancing the candidate through a global Phase III clinical trial and has received Fast Track designation from the U.S. FDA.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -2.7 | — |
| Q2 2025 | 0 | — | -4 | — |
| Q3 2025 | 0 | — | -4.2 | — |
| Q4 2025 | 0 | — | -7.9 | — |
| Q1 2026 | 0 | — | -5.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: LexinFintech Holdings Ltd. (LX), Minerva Neurosciences, Inc. (NERV), Capstone Energy+, Inc. (CEPL), Energy Services of America Corporation (ESOA), Lifetime Brands, Inc. (LCUT), Patriot Acquisition Corp. (PTAC)